Search

Displaying results 5241 - 5250 of 10000 in total
  1. Drug

    SLV319

    go.drugbank.com/drugs/DB05077
    Experimental

    It is developed for the treatment of obesity and other metabolic disorders. … SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor.

  2. Drug

    Human papillomavirus type 18 L1 capsid protein residues 2-472 antigen

    go.drugbank.com/drugs/DB10995
    ApprovedWithdrawn

    Mixtures: CERVARIX SUSPENSION FOR INJECTION
  3. Drug

    Plozalizumab

    go.drugbank.com/drugs/DB12520
    Investigational

    Plozalizumab has been investigated for the treatment of Atherosclerosis. … The recruitment of macrophages to the arterial wall is believed to be a critical step in the development of atherosclerosis.

  4. Drug

    NBI-6024

    go.drugbank.com/drugs/DB05819
    Investigational

    NBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.

  5. Drug

    Dibekacin

    go.drugbank.com/drugs/DB13270
    Approved

    Dibekacin is an aminoglycoside antibiotic marketed in Japan [L5623].

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  6. Indication

    Lenticular opacities

    go.drugbank.com/conditions/DBCOND0010192
    Drugs: Bendazac
    Synonyms: Cataract form (observable entity)
  7. Drug

    Cobalt chloride

    go.drugbank.com/drugs/DB14206
    Approved

    Synonyms: Cobalt(II) chloride, Kobalt(II)-chloridCategories: Compounds used in a research, industrial, or household setting
  8. Drug

    Dihydrostreptomycin

    go.drugbank.com/drugs/DB11512
    ApprovedVet approvedWithdrawn

    The FDA withdrew its approval for the use of all drug products containing dihydrostreptomycin sulfate.[L43942] … Dihydrostreptomycin is an aminoglycoside antibiotic. In humans, the use of dihydrostreptomycin has been associated with ototoxicity.

    Synonyms: N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-a-L-glucopyranosyl]-3-C-(hydroxymethyl)-a-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine, N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-α-L-glucopyranosyl]-3-C-(hydroxymethyl)-α-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine
  9. Drug

    MIV-701

    go.drugbank.com/drugs/DB05736
    Experimental

    MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.

  10. Drug

    Apazunersen

    go.drugbank.com/drugs/DB16981
    Investigational

    Apazunersen is an antisense oligonucleotide designed to target and inhibit the expression of UBE3A-AS. It is being investigated for the treatment of Angelman Syndrome.[L46772]

    Categories: Antisense Oligonucleotide Specific to the Antisense Transcript of UBE3A